ストックスクリーナーアプリを入手
13.93
0.85%
-0.195
前日終値:
$14.12
開ける：
$14.13
24時間の取引高:
93,201
Relative Volume:
0.09
時価総額：
$2.14B
収益：
$340.81M
当期純損益:
$-419.65M
株価収益率:
-4.886
EPS:
-2.85
ネットキャッシュフロー:
$-402.10M
1週間 パフォーマンス:
-5.53%
1か月 パフォーマンス:
-25.89%
6か月 パフォーマンス:
-52.17%
1年 パフォーマンス:
-29.58%
1日の値動き範囲:
$13.86
$14.31
1週間の範囲:
$13.91
$14.98
52週間の値動き範囲:
$13.91
$33.33
Denali Therapeutics Inc Stock (DNLI) Company Profile
名前
Denali Therapeutics Inc
セクター
電話
(650) 866-8548
住所
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
DNLI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
13.92 | 2.14B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.52 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.90 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
588.05 | 35.74B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.70 | 35.58B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.85 | 27.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-07 | 再開されました | Morgan Stanley | Overweight |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2025-01-07 | 開始されました | Robert W. Baird | Outperform |
| 2025-01-03 | 開始されました | William Blair | Outperform |
| 2024-12-16 | アップグレード | Stifel | Hold → Buy |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-10-07 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | 開始されました | Citigroup | Buy |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-09-06 | 開始されました | B. Riley Securities | Buy |
| 2023-01-30 | 開始されました | SVB Securities | Outperform |
| 2022-12-05 | 開始されました | Cowen | Outperform |
| 2022-11-02 | アップグレード | BTIG Research | Neutral → Buy |
| 2022-11-02 | 開始されました | BofA Securities | Buy |
| 2022-06-23 | 開始されました | Berenberg | Buy |
| 2021-12-10 | 再開されました | Raymond James | Mkt Perform |
| 2021-09-21 | 開始されました | Oppenheimer | Outperform |
| 2021-09-01 | 開始されました | SMBC Nikko | Outperform |
| 2021-05-18 | 開始されました | UBS | Buy |
| 2021-02-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-02-10 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-16 | ダウングレード | BTIG Research | Buy → Neutral |
| 2020-09-14 | 再開されました | JP Morgan | Overweight |
| 2020-08-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-13 | アップグレード | Evercore ISI | In-line → Outperform |
| 2020-02-28 | アップグレード | Wedbush | Neutral → Outperform |
| 2020-02-24 | 開始されました | Jefferies | Buy |
| 2020-02-19 | 開始されました | Stifel | Hold |
| 2020-01-27 | アップグレード | Goldman | Neutral → Buy |
| 2019-09-26 | 開始されました | Wedbush | Neutral |
| 2019-09-13 | 開始されました | Nomura | Buy |
| 2019-08-09 | 開始されました | BTIG Research | Buy |
| 2019-06-26 | 開始されました | H.C. Wainwright | Buy |
| 2018-11-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-11-12 | 開始されました | Janney | Buy |
| 2018-03-12 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2018-01-02 | 開始されました | Evercore ISI | Outperform |
| 2018-01-02 | 開始されました | Goldman | Neutral |
| 2018-01-02 | 開始されました | JP Morgan | Overweight |
| 2018-01-02 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Denali Therapeutics Inc (DNLI) 最新ニュース
Denali Therapeutics stock hits 52-week low at $13.95 - Investing.com
Exponential Growth Expected for Blood Brain Barrier Market With - openPR
Denali Therapeutics: Vast Pipeline, First Approval Up Ahead (NASDAQ:DNLI) - Seeking Alpha
Why You Shouldn't Bet Against Denali (DNLI) Stock - Barchart
(DNLI) On The My Stocks Page - Stock Traders Daily
Denali Starts Dosing in Phase II Parkinson's Disease Study - MSN
Denali Therapeutics (NASDAQ:DNLI) Given New $28.00 Price Target at Bank of America - Defense World
Denali Therapeutics (NASDAQ:DNLI) Shares Down 8.9% on Analyst Downgrade - Defense World
Why Denali Therapeutics Shares Are Tumbling - TipRanks
Bank of New York Mellon Corp Decreases Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World
Proficio Capital Partners LLC Makes New $514,000 Investment in Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World
Denali Therapeutics (NASDAQ:DNLI) Earns Overweight Rating from Analysts at Morgan Stanley - Defense World
How the (DNLI) price action is used to our Advantage - Stock Traders Daily
B. Riley Forecasts Lower Earnings for Denali Therapeutics - Defense World
Denali's ALS programme suffers another setback - pharmaphorum
What is B. Riley’s Forecast for DNLI FY2029 Earnings? - Defense World
B. Riley Reaffirms Buy Rating for Denali Therapeutics (NASDAQ:DNLI) - Defense World
Denali Therapeutics Ends ALS Trial Extension, Analyst Stays Optimistic Despite Trial Setback - Benzinga India
Denali Therapeutics discontinues active treatment extension in eIF2B Regimen G - TipRanks
Denali Therapeutics Discontinues DNL343 ALS Trial - TipRanks
DNLI stock touches 52-week low at $14.55 amid market challenges - Investing.com Australia
B. Riley Trims Price Target on Denali Therapeutics to $35 From $38, Keeps Buy Rating - Marketscreener.com
Denali Therapeutics (NASDAQ:DNLI) Sets New 12-Month Low Following Analyst Downgrade - Defense World
DNLI stock touches 52-week low at $14.55 amid market challenges By Investing.com - Investing.com South Africa
Denali Therapeutics price target lowered to $42 from $50 at Oppenheimer - Yahoo Finance
Is Denali Therapeutics Inc. (DNLI) Among Jeff Bezos’ Investments in 2025? - Insider Monkey
Oppenheimer Adjusts Denali Therapeutics Price Target to $42 From $50, Maintains Outperform Rating - Marketscreener.com
Deutsche Bank Adjusts Denali Therapeutics Price Target to $29 From $31, Maintains Buy Rating - Marketscreener.com
Denali Therapeutics: Why Analysts Remain Optimistic - TipRanks
Denali Therapeutics’ (DNLI) “Outperform” Rating Reiterated at William Blair - Defense World
What is HC Wainwright’s Forecast for DNLI Q1 Earnings? - Defense World
Denali Therapeutics (NASDAQ:DNLI) Price Target Raised to $87.00 - Defense World
Denali Q4 Earnings Beat Estimates, Hunter Syndrome Drug in Focus - MSN
Jeff Bezos Investments in 2025: 12 Companies Bezos Is Investing In - Insider Monkey
Y Intercept Hong Kong Ltd Has $734,000 Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
William Blair Reiterates "Outperform" Rating for Denali Therapeutics (NASDAQ:DNLI) - MarketBeat
Denali Therapeutics closes down 11% as 2025 operating expenses seen weighing - MSN
Denali Therapeutics (NASDAQ:DNLI) Posts Quarterly Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
Wedbush Adjusts Price Target on Denali Therapeutics to $32 From $33, Maintains Outperform Rating - Marketscreener.com
Positive Outlook for Denali Therapeutics: Strategic Progress and Promising Developments Support Buy Rating - TipRanks
Denali Therapeutics: Promising ETV Platform and Strategic Advancements Justify Buy Rating - TipRanks
Denali stock price target cut to $80 by H.C. Wainwright - Investing.com
Denali Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Denali Therapeutics reports Q4 EPS (67c), consensus (85c) - TipRanks
Denali Therapeutics Files For Mixed Shelf Size Not DisclosedSEC Filing -February 27, 2025 at 05:14 pm EST - Marketscreener.com
Denali Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Denali Therapeutics Signs New Equity Distribution Deal - TipRanks
Denali Therapeutics Inc. SEC 10-K Report - TradingView
Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - GlobeNewswire
Can Denali's Hunter Syndrome Drug Breakthrough Offset $422M Annual Loss? - StockTitan
Trading (DNLI) With Integrated Risk Controls - Stock Traders Daily
Denali Therapeutics Inc (DNLI) 財務データ
収益
当期純利益
現金流量
EPS
Denali Therapeutics Inc (DNLI) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Ho Carole | Chief Medical Officer |
Jan 07 '25 |
Sale |
20.81 |
2,907 |
60,495 |
175,673 |
| Schuth Alexander O. | COFO and Secretary |
Jan 06 '25 |
Sale |
20.22 |
12,255 |
247,796 |
247,215 |
| Schuth Alexander O. | COFO and Secretary |
Jan 07 '25 |
Sale |
20.81 |
2,907 |
60,495 |
244,308 |
| Watts Ryan J. | President and CEO |
Jan 06 '25 |
Sale |
20.22 |
29,266 |
591,759 |
260,721 |
| Watts Ryan J. | President and CEO |
Jan 07 '25 |
Sale |
20.81 |
7,650 |
159,196 |
253,071 |
| Krognes Steve E. | Director |
Jan 07 '25 |
Sale |
20.81 |
3,339 |
69,485 |
25,757 |
1.66%
4.32%
大文字化:
|
ボリューム (24 時間):